14.94
price down icon6.16%   -0.98
after-market アフターアワーズ: 14.94
loading
前日終値:
$15.92
開ける:
$16.24
24時間の取引高:
1.71M
Relative Volume:
1.24
時価総額:
$1.74B
収益:
$674.41M
当期純損益:
$-173.05M
株価収益率:
-9.7373
EPS:
-1.5343
ネットキャッシュフロー:
$-48.07M
1週間 パフォーマンス:
-5.68%
1か月 パフォーマンス:
-16.21%
6か月 パフォーマンス:
+41.61%
1年 パフォーマンス:
+6.33%
1日の値動き範囲:
Value
$14.91
$16.24
1週間の範囲:
Value
$14.91
$16.44
52週間の値動き範囲:
Value
$9.82
$21.45

Novocure Ltd Stock (NVCR) Company Profile

Name
名前
Novocure Ltd
Name
セクター
Healthcare (1064)
Name
電話
44 (0)15 3475 6700
Name
住所
NO. 4 THE FORUM, ST. HELIER
Name
職員
1,605
Name
Twitter
@novocure
Name
次回の収益日
2026-10-29
Name
最新のSEC提出書
Name
NVCR's Discussions on Twitter

Compare NVCR vs ABT, MDT, SYK, BSX, EW

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NVCR icon
NVCR
Novocure Ltd
14.94 1.84B 674.41M -173.05M -48.07M -1.5343
ABT icon
ABT
Abbott Laboratories
97.50 175.27B 46.59B 5.41B 7.38B 3.0938
MDT icon
MDT
Medtronic Plc
86.38 113.38B 36.36B 4.84B 5.43B 3.7261
SYK icon
SYK
Stryker Corp
275.43 104.47B 25.27B 3.34B 4.57B 8.6334
BSX icon
BSX
Boston Scientific Corp
42.60 63.65B 20.62B 3.56B 3.48B 2.3847
EW icon
EW
Edwards Lifesciences Corp
85.15 49.74B 6.30B 1.07B 1.09B 1.8406

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-25 ダウングレード Wells Fargo Overweight → Equal Weight
2025-07-08 開始されました Ladenburg Thalmann Buy
2024-12-02 アップグレード Evercore ISI In-line → Outperform
2024-10-16 アップグレード H.C. Wainwright Neutral → Buy
2023-11-20 再開されました JP Morgan Neutral
2023-08-28 ダウングレード H.C. Wainwright Buy → Neutral
2023-08-08 アップグレード Piper Sandler Neutral → Overweight
2023-08-04 開始されました SVB Securities Outperform
2023-07-31 アップグレード Evercore ISI Underperform → In-line
2023-06-07 アップグレード Wedbush Underperform → Neutral
2023-05-16 アップグレード Wells Fargo Equal Weight → Overweight
2023-03-17 ダウングレード JP Morgan Neutral → Underweight
2023-01-06 ダウングレード Wells Fargo Overweight → Equal Weight
2023-01-05 繰り返されました H.C. Wainwright Buy
2022-11-29 アップグレード Wells Fargo Equal Weight → Overweight
2022-10-24 ダウングレード Piper Sandler Overweight → Neutral
2022-07-05 ダウングレード Evercore ISI In-line → Underperform
2022-05-16 開始されました H.C. Wainwright Buy
2022-02-08 開始されました Loop Capital Buy
2022-02-02 アップグレード Oppenheimer Perform → Outperform
2022-01-20 アップグレード Truist Hold → Buy
2022-01-03 アップグレード Evercore ISI Underperform → In-line
2021-07-01 ダウングレード Mizuho Buy → Neutral
2021-04-14 ダウングレード Wedbush Neutral → Underperform
2021-01-25 繰り返されました Piper Sandler Overweight
2020-09-23 開始されました Northland Capital Outperform
2020-09-18 ダウングレード Wells Fargo Overweight → Equal Weight
2020-09-17 ダウングレード Truist Buy → Hold
2020-06-01 再開されました Oppenheimer Perform
2020-05-01 ダウングレード Oppenheimer Outperform → Perform
2020-04-09 ダウングレード Evercore ISI In-line → Underperform
2020-03-05 アップグレード Wells Fargo Equal Weight → Overweight
2020-01-02 ダウングレード Evercore ISI Outperform → In-line
2019-07-29 アップグレード SunTrust Hold → Buy
2019-07-26 ダウングレード JP Morgan Overweight → Neutral
2019-07-26 ダウングレード Wedbush Outperform → Neutral
2019-03-20 開始されました SunTrust Hold
2018-11-02 ダウングレード Wells Fargo Outperform → Market Perform
2018-07-16 開始されました Evercore ISI Outperform
2018-04-18 繰り返されました Mizuho Buy
2018-02-23 繰り返されました Mizuho Buy
2017-05-24 アップグレード Wells Fargo Market Perform → Outperform
2016-07-29 繰り返されました Wedbush Outperform
2016-01-19 開始されました Barclays Underweight
2015-12-02 開始されました Deutsche Bank Hold
すべてを表示

Novocure Ltd (NVCR) 最新ニュース

pulisher
Oct 01, 2026

Novocure Receives Approval In Japan For Optune Pax For The Treatment Of Unresectable Locally Advanced Pancreatic Cancer - marketscreener.com

Oct 01, 2026
pulisher
Oct 01, 2026

Japan approves a wearable device to use with chemo for advanced pancreatic cancer. - Stock Titan

Oct 01, 2026
pulisher
Oct 01, 2026

A results call is set for 8 a.m. Oct. 29, when Novocure will discuss third-quarter results. - Stock Titan

Oct 01, 2026
pulisher
Sep 29, 2026

Price to earnings forward of NovoCure Ltd. – HAN:038 - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

ETFs Investing in NovoCure Ltd. Stocks - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

Tariff Cuts Put NovoCure Stock And Medical Exporters Back In Focus - Simply Wall Street

Sep 29, 2026
pulisher
Sep 25, 2026

Novocure Stock Price Forecast. Should You Buy NVCR? - StockInvest.us

Sep 25, 2026
pulisher
Sep 24, 2026

NovoCure stock reports 15.6 percent Q2 revenue growth - AD HOC NEWS

Sep 24, 2026
pulisher
Sep 24, 2026

NovoCure Limited (NVCR) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 24, 2026
pulisher
Sep 24, 2026

Is NovoCure (NVCR) Undervalued On TTFields Validation And Board Change? - simplywall.st

Sep 24, 2026
pulisher
Sep 23, 2026

NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall - Yahoo Finance Singapore

Sep 23, 2026
pulisher
Sep 22, 2026

NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change - Yahoo Finance Singapore

Sep 22, 2026
pulisher
Sep 20, 2026

Growth Plan Might Change The Case For Investing In NovoCure Stock (NVCR) - simplywall.st

Sep 20, 2026
pulisher
Sep 18, 2026

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even - TradingView

Sep 18, 2026
pulisher
Sep 17, 2026

Is It Too Late to Buy NovoCure Ltd (NVCR) After 3.1% Rally? GF V - GuruFocus

Sep 17, 2026
pulisher
Sep 14, 2026

Novocure at Morgan Stanley conference: growth, discipline and expansion By Investing.com - Investing.com India

Sep 14, 2026
pulisher
Sep 14, 2026

NovoCure Limited at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus

Sep 14, 2026
pulisher
Sep 14, 2026

Novocure at Morgan Stanley conference: growth, discipline and expansion - Investing.com

Sep 14, 2026
pulisher
Sep 13, 2026

NovoCure (NVCR) Stock Looks Cheap On Sales But Weak On Adoption Risk - simplywall.st

Sep 13, 2026
pulisher
Sep 10, 2026

NovoCure (NASDAQ: NVCR) Announces Board Vacancy Following Timothy Scannell's Departure on September 2, 2026 - kalkinemedia.com

Sep 10, 2026
pulisher
Sep 09, 2026

NovoCure at Wells Fargo healthcare conference: launch momentum builds By Investing.com - Investing.com South Africa

Sep 09, 2026
pulisher
Sep 09, 2026

NovoCure at Wells Fargo healthcare conference: launch momentum builds - Investing.com

Sep 09, 2026
pulisher
Sep 09, 2026

Novocure Ltd Announces Retirement of Timothy Scannell from the Board, Effective September 2, 2026 - marketscreener.com

Sep 09, 2026
pulisher
Sep 09, 2026

Timothy Scannell retires from NovoCure board, seat vacated Sept 2, 2026 - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

NovoCure (NASDAQ: NVCR) director steps down with no dispute - Stock Titan

Sep 09, 2026
pulisher
Sep 07, 2026

Novocure Reports Patient Data Exposure in Cybersecurity Incident - Yahoo Finance

Sep 07, 2026
pulisher
Sep 04, 2026

NOVOCURE LTD (NVCR) Stock Chart - ChartMill

Sep 04, 2026
pulisher
Sep 04, 2026

Novocure Ltd (NVCR) Key Financial Ratios – Valuation, Profitability & More - Value Research

Sep 04, 2026
pulisher
Sep 03, 2026

Cash flow from operating activities of NovoCure Ltd. – HAM:038 - TradingView

Sep 03, 2026
pulisher
Sep 03, 2026

Net debt of NovoCure Ltd. – HAM:038 - TradingView

Sep 03, 2026
pulisher
Sep 03, 2026

NovoCure says cyberattack caused patient data exposure - Yahoo Finance

Sep 03, 2026
pulisher
Sep 02, 2026

Basic earnings per share (basic EPS) of NovoCure Ltd. – HAM:038 - TradingView

Sep 02, 2026
pulisher
Sep 02, 2026

NovoCure (NVCR) Stock May Be Cheap Based On Sales Growth Risk - simplywall.st

Sep 02, 2026
pulisher
Sep 02, 2026

NewsNovocure discloses cyberattack exposing records of more than 1,400 US cancer patients - teiss

Sep 02, 2026
pulisher
Sep 02, 2026

Novocure Announces Upcoming Investor Events - finance.yahoo.com

Sep 02, 2026
pulisher
Sep 01, 2026

NovoCure (NASDAQ: NVCR) Data Breach Exposes IDs Linked to Over 1,400 U.S. Patient Records - Kalkine Media

Sep 01, 2026
pulisher
Sep 01, 2026

Novocure Reveals Major Breach of Cancer Patient Records - sqmagazine.co.uk

Sep 01, 2026
pulisher
Sep 01, 2026

Oncology firm Novocure says cyberattack exposed US patient records - CNA

Sep 01, 2026
pulisher
Sep 01, 2026

NVCR Looks 3.4% Undervalued on GF Value™ Amid Cybersecurity Inci - GuruFocus

Sep 01, 2026
pulisher
Sep 01, 2026

Novocure reports data access affecting patient IDs for 1,400+ U.S. records; no device access - TradingView

Sep 01, 2026
pulisher
Sep 01, 2026

NovoCure cyber breach hits 1,400+ patient records - Stock Titan

Sep 01, 2026
pulisher
Sep 01, 2026

Novocure Ltd (NVCR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Sep 01, 2026
pulisher
Aug 30, 2026

Novocure Ltd (NVCR) Peer Comparison – Compare with Others - Value Research

Aug 30, 2026
pulisher
Aug 30, 2026

Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates? - simplywall.st

Aug 30, 2026
pulisher
Aug 29, 2026

NovoCure Limited (NVCR) Stock Price & News - Syfe

Aug 29, 2026
pulisher
Aug 28, 2026

Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance

Aug 28, 2026
pulisher
Aug 22, 2026

Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors? - simplywall.st

Aug 22, 2026
pulisher
Aug 21, 2026

A Look at NovoCure Ltd (NVCR) After 3.7% Decline -- GF Value $18 - GuruFocus

Aug 21, 2026
pulisher
Aug 21, 2026

NovoCure (NASDAQ:NVCR) Shares Down 4%What's Next? - MarketBeat

Aug 21, 2026
pulisher
Aug 20, 2026

Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Novocure | 8-K: Current report - Moomoo

Aug 20, 2026

Novocure Ltd (NVCR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Novocure Ltd (NVCR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Leonard Frank X
Chief Executive Officer
Jun 04 '26
Sale
17.93
34,273
614,635
459,520
ZBH ZBH
$88.29
price up icon 0.26%
STE STE
$208.54
price down icon 0.38%
PHG PHG
$23.92
price up icon 0.46%
$64.29
price up icon 0.48%
$85.36
price down icon 1.01%
EW EW
$85.15
price down icon 0.05%
大文字化:     |  ボリューム (24 時間):